Previously, CSCs have been identified in MM 7 by the evidence that the CD138-/CD19+ fraction of MM has a greater clonogenic potential and the phenotype of a memory B-cell (CD19+, CD27+), resulting in the development of refractory clones and disease relapse8. The gene discussed is CD19; the disease is Miyoshi myopathy.